Garrison Financial Corp reduced its stake in shares of Sanofi (NYSE:SNY) by 0.8% during the second quarter, Holdings Channel reports. The fund owned 8,295 shares of the company’s stock after selling 65 shares during the period. Garrison Financial Corp’s holdings in Sanofi were worth $397,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Guggenheim Capital LLC increased its position in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares during the last quarter. Capstone Asset Management Co. increased its position in shares of Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock valued at $3,719,000 after buying an additional 4,635 shares during the last quarter. Atria Investments LLC increased its position in shares of Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock valued at $334,000 after buying an additional 602 shares during the last quarter. BLB&B Advisors LLC acquired a new position in shares of Sanofi during the first quarter valued at about $202,000. Finally, Cullinan Associates Inc. increased its position in shares of Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the last quarter. Hedge funds and other institutional investors own 9.96% of the company’s stock.

Shares of Sanofi (SNY) opened at 47.55 on Friday. The stock’s 50 day moving average price is $47.99 and its 200-day moving average price is $46.11. The company has a market cap of $119.42 billion, a P/E ratio of 11.23 and a beta of 0.88. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24.

Sanofi (NYSE:SNY) last released its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities analysts expect that Sanofi will post $3.26 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Sanofi (NYSE:SNY) Shares Sold by Garrison Financial Corp” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2017/08/12/sanofi-nysesny-shares-sold-by-garrison-financial-corp.html.

Several equities analysts have issued reports on SNY shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, April 20th. Zacks Investment Research downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, BidaskClub downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.